| Project/Area Number |
18K16272
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Uematsu Satomi 東北大学, 医学系研究科, 大学院非常勤講師 (30811476)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 膵島移植 / Fibroblast Growth Factor / リコンビナントペプチド / ADSCs / 皮下膵島移植 / I型コラーゲン様リコンビナントペプチド / 血管新生細胞外マトリックス（ECM） / ADSCｓ / 皮下移植 / Recombinant Peptide / Extracellular Matrix |
|---|
| Outline of Final Research Achievements |
We created a device using Fibroblast Growth Factor and demonstrated the importance of neovascularization in improving the survival rate of subcutaneous islet transplantation. We also established a safe and effective method for constructing a subcutaneous vascular development using a new material, type I Collagen-like recombinant peptide (RCP).
and accomplished an improvement in the survival rate of subcutaneous islet transplantation, which is equivalent to that of conventional portal vein transplantation.
In addition, we verified the group in which Adipose-derived stem cells (ADSCs) were added to RCP (RCP + ADSCs group), and we reasonably confident that the neovascular enhancement effect and the up-regulation of ECM at the transplant site and around the islet graft capsule would promote islet engraftment synergistically.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究の目的は、重症１型糖尿病の根治療法において、リスクが高い従来の経門脈的膵島移植に代わる低侵襲な皮下膵島移植の開発である。我々はFibroblast Growth Factorや新規素材であるI型Collagen様リコンビナントペプチド（RCP）、血管新生作用を有するAdipose-derived stem cells (ADSCs)を用いて安全で効果的な皮下血管床構築法を確立することにより、従来の経門脈移植と同等の皮下膵島移植の生着率向上を実現した。
|
